Re My comment on Valuation of Cvac
Refer Prima Presentation Dated 27th Feb 2015 slide 40
Feb. 2014. Valeant (world’s No. 34 pharma company) acquired Provenge for 400 Million.
Provenge® 2014 US$304m net product revenue, up 7% -4Q14: Cash-flow break-even
Look at the figures Provane was / is a market leader and did great for a Yearly revenue of 304 Million at break-even so efficiency at production, distribution and marketing would make it profitable year 2 and so on.
So, given the newness of Cvac but with better results.. there is promise both in development and One off License sale
- Forums
- ASX - By Stock
- PreMarket22May_Nasdaq
Re My comment on Valuation of Cvac Refer Prima Presentation...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
32.5¢ |
Change
-0.030(8.45%) |
Mkt cap ! $475.7M |
Open | High | Low | Value | Volume |
34.0¢ | 34.5¢ | 31.5¢ | $1.965M | 5.972M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
29 | 232992 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 110260 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 224836 | 0.320 |
19 | 470004 | 0.315 |
11 | 68673 | 0.310 |
14 | 185773 | 0.305 |
18 | 462885 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 101141 | 7 |
0.330 | 391155 | 12 |
0.335 | 86980 | 8 |
0.340 | 474757 | 9 |
0.345 | 100299 | 6 |
Last trade - 14.38pm 15/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online